Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings

Annals of Nuclear Medicine

Volumn 26, Issue 9, 2012, Pages 689-697

  Kuyumcu, Serkan ^a   Adalet, Isik ^a   Sanli, Yasemin ^a   Turkmen, Cuneyt ^a   Ozkan, Zeynep Gozde ^a   Yilmazbayhan, Dilek ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

FDG PET; Ki 67; Pulmonary carcinoid; Somatostatin receptor scintigraphy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG ATYPICAL CARCINOID; LUNG CANCER; LUNG NODULE; LUNG SCINTISCANNING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY CARCINOID TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY;

ADOLESCENT; ADULT; AGED; CARCINOID TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84872114212     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0628-x     Document Type: Article

References (38)

1. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669-92.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
3. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255-65.
4. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumours. Cancer. 2008;113: 5-21.
5. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA. Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer. 2009;115:4434-41.
6. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR. 1998;170:1369-73.
7. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett Jr. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255-60.
8. Wartski M, Alberini JL, Leroy-Ladurie F, De Montpreville V, Nguyen C, Corone C, et al. Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging. Clin Nucl Med. 2004;29:752-3. (Pubitemid 39410835)
9. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol. 2004;15:275-91.
10. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2010;21:548-55.
11. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727-34.
12. Laitinen KLJ, Soini Y, Mattila J, Paakko P. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer. 2000;88:1590-8. (Pubitemid 30183144)
13. Yellin A, Zwas ST, Rozenman J, Simansky DA, Goshen E. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J. 2005;7:712-6. (Pubitemid 41700795)
14. Buchmann I, Henze M, Engelbrecht S, Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68 Ga-DOTATOC PET and 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-26.
15. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe(1), Tyr(3)-octreotate) and 18F-FDG. Cancer. 2008;112:2447-55.
16. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTATyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
17. Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Intern Med. 2010;25:386-91.
18. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010;68:66-71.
19. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006;26:41-57. (discussion 57-58).
20. Krüger S, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med. 2006;260:545-50.
21. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: a head-tohead comparison of somatostatin receptor scintigraphy, 123IMIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704-12.
22. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68 Ga-DOTATATE and 18F-FDG PET/ CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927-32.
23. Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG PET/CT and [68 Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011;11:70-5.
24. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-46.
25. Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994;21:497-502.
26. Ferolla P, Faggiano A, Avenia N, Milone F, Masone S, Giampaglia F, et al. Epidemiology of non gastroenteropancreatic (neuro)endocrine tumours. Clin Endocrinol. 2007;66:1-6. (Pubitemid 44952487)
27. Ferguson MK, Landreneau RJ, Hazelrigg SR, Altorki NK, Naunheim KS, Zwischenberger JB, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18:156-61.
28. Filosso PL, Rena O, Donati G, Casadio C, Ruffini E, Papalia E, et al. Bronchial carcinoid tumours: surgical management and long-term outcome. J Thorac Cardiovasc Surg. 2002;123:303-9. (Pubitemid 34127118)
29. Harpole DH, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumours: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992;54:50-5.
30. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-29.
31. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647-51.
32. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002;37:127-35.
33. Schrevens L, Vansteenkiste J, Deneffe G, De Leyn P, Verbeken E, Vandenberghe T, et al. Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience. Lung Cancer. 2004;43:39-45.
34. Thomas CF Jr, Tazelaar HD, Jett Jr. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest. 2001;119:1143-50.
35. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858-64.
36. Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, et al. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (C10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96:665-71.
37. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221-32.
38. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18Ffluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978-85.